Virus Treatments as Bird Flu Make Headlines (NASDAQ: $AEMD) (NASDAQ: $MRNA)
(NYSE: $PFE) (NASDAQ: $IBRX) (NASDAQ: $ALGS) @moderna_tx
@pfizer @ImmunityBio @AligosThera
June
10, 2024 - Investorideas.com, a go-to investing
platform, releases the second of a two-part series looking at news and
developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical
therapeutic company focused on developing products to treat cancer and
life-threatening infectious diseases.
The
threat of viruses is back in the news with multiple news sources, including the
Guardian reporting, ”The
World Health Organization (WHO) has said a man’s death in Mexico was caused by
a strain of bird flu called H5N2 that has never before been found in a human.”
The
WHO said Wednesday it wasn’t clear how the person became infected. “Although
the source of exposure to the virus in this case is currently unknown, A (H5N2)
viruses have been reported in poultry in Mexico,” it said in a statement.
Continued: “Scientists are on
alert for changes in the virus that could signal that bird flu is adapting to
spread more easily among humans.
Continued: “But the UN agency said Wednesday said the
current risk of the bird flu virus to the general population in Mexico is low.”
With
global populations and economies still feeling the impact of Covid-19, any
virus threat is going to make headlines.
As
viruses make headlines, companies are seeking solutions and not all are focused
on vaccine development.
This news is paid advertisement/ news
disseminated on behalf of/issued on behalf of Aethlon Medical Inc.
Read this article
featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/06101Virus-Treatments-Bird-Flu.asp
Aethlon Medical,
Inc.
(Nasdaq: AEMD) just recently announced an update on its
technology for cancer treatment on its planned phase 1 safety, feasibility and
dose-finding clinical trials of its Hemopurifier® in patients with solid tumors
who have stable or progressive disease during anti-PD-1 monotherapy treatment,
such as Keytruda® or Opdivo®.
The
Aethlon Hemopurifier® technology is designed for the rapid depletion of
cancer-promoting exosomes and circulating viruses. The United States Food and
Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough
Device” for the treatment of individuals with advanced or metastatic cancer who
are either unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in the development
or severity of the disease; and life-threatening viruses that are not addressed
with approved therapies.
As
reported previously, separate from its current focus on cancer treatment,
Aethlon has investigated the potential for the use of the Hemopurifier® in viral diseases.
According
to their SEC filing, “We also believe
the Hemopurifier can be part of the broad-spectrum treatment of
life-threatening highly glycosylated, or carbohydrate coated, viruses that are
not addressed with an already approved treatment. In small-scale or early
feasibility human studies, the Hemopurifier has been used in the past to treat
individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and
Ebola.”
“Additionally,
in vitro, the Hemopurifier has been demonstrated to capture Zika virus, Lassa
virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus,
Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses,
H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus and the
reconstructed Spanish flu virus of 1918. In several cases, these studies were
conducted in collaboration with leading government or non-government research
institutes.”
Recently,
Zacks reported that
“Vaccine Stocks Rise on Growing Threat of Bird Flu Infections”
“Shares
of several vaccine makers soared after reports suggest that the Biden
administration is in discussions with Moderna (NASDAQ: MRNA) and Pfizer (NYSE:PFE) to set up a possible vaccine
program aimed at preventing the spread of the H5N1 virus, also known as bird
flu, in humans.”
Continued: “These reports
came to light after the discovery of two cases of H5N1 virus in dairy farm
workers in Texas and Michigan this year. Both these workers experienced
symptoms in the eye after coming into contact with dairy cows infected with the
H5N1 virus.”
But
the treatment of viral diseases has other options including immunotherapy.
ImmunityBio
(NASDAQ: IBRX), a clinical-stage
immunotherapy company, announced earlier this year
the publication of preclinical data in the online issue of Science, First
Release indicating that combination therapy with N-803, an IL-15 superagonist,
and broadly neutralizing antibodies may potentially enable the immune system to
manage human immunodeficiency virus (HIV) without the need for antiretroviral
treatment.
From the news: In the preclinical
non-human primate study, researchers led by Dr. James Whitney, Ph.D. and funded
by the National Institutes of Health and the National Institute of Allergy and
Infectious Diseases (NIAID) demonstrated that using N-803, in combination with
broadly neutralizing antibodies (bNAbs), led to sustained viral control after
discontinuation of antiretroviral therapy (ART) in ART-suppressed rhesus
macaques infected with simian-human immunodeficiency virus AD8 (SHIV-AD8).
Treatment with N-803 and bNAbs led to immune activation and transient viremia,
but only limited reductions in the SHIV reservoir. Upon ART discontinuation,
all animals experienced viral rebound, followed by long-term virus control for
up to 10 months in approximately 70% of those treated with N-803 and bNAbs.
"The
viral reservoir in people with HIV is established within the first few days of
infection and cannot be eliminated by the body’s immune system or currently
available treatments, representing a significant obstacle in curing an
established HIV infection," said James B. Whitney, M.D., Study Author and
Researcher at the Center for Virology and Vaccine Research at Beth Israel
Deaconess Medical Center and Harvard Medical School. "When combined with
broadly neutralizing antibodies, N-803 has the potential to provide viral
control without significant reduction in the viral reservoir, which further
suggests that the complete eradication of this reservoir may not be required to
induce sustained remission after discontinuing antiretroviral therapy."
Taking
another approach to viral diseases, Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical
stage biopharmaceutical company that was founded in 2018 with the mission to
become a world leader in the treatment of liver and viral diseases. Aligos’
strategy is to harness the deep expertise and decades of drug development
experience its team has in liver and viral diseases to discover and develop
potentially best-in-class therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH) and viruses with high unmet medical need such as
hepatitis B and coronaviruses.
The
Company just announced positive data from
six poster presentations at the European Association for the Study of the Liver
(EASL) Congress 2024, being held June 5-8 in Milan, Italy.
From the news: Reported for the
first time were antiviral and safety data in HBeAg-negative CHB subjects who
received a daily single dose of 300 mg ALG-000184 monotherapy for ≤60 weeks. In
all 11 subjects (100%), complete suppression of HBV DNA (<LLOQ 10 IU/mL) and
RNA (<LLOQ 10 copies/mL) were noted, with reduction in HBcrAg levels
indicating inhibition of HBV replication, as well as inhibition of cccDNA
establishment/replenishment. In both patient populations, ALG-000184 continues
to be well tolerated with no viral breakthrough.
With
bird flu cases on the rise, retail investors are once again on the hunt for
stocks with potential solutions.
As
Bloomberg reported recently,”Mounting cases of
bird flu in humans is luring the day trading crowd to snap up stock in vaccine
developers. It’s a familiar setup for industry veterans who have witnessed past
trading frenzies at the first signs of an outbreak.”
This
won’t be the last viral outbreak. There are more viruses than stars in the
universe. And there are multiple solutions to treating viruses in addition to
vaccines.
Read
part one of the series at Investorideas.com
https://www.investorideas.com/news/2024/biotech/06031Blood-Purification-Medical-Devices.asp
Research biotech and medical device/
tech stocks at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all. Our original branded content includes podcasts such as Exploring
Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for sectors including mining, crypto, renewable
energy, gaming, biotech, tech, sports and more. Public companies within the
sectors we cover can use our news publishing and content creation services to
help tell their story to interested investors. Paid content is always
disclosed.
Disclaimer/Disclosure: This news article
featuring AEMD is a paid for news release on Investorideas.com. AEMD is a paid featured
medical tech
stock on our site. Our site does not make
recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp
Learn more about publishing your news release and our other news services and
prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Global investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact
Investorideas.com
800-665-0411
Biotech
Industry Stocks- investing ideas in biotechnology stocks, medical technology
and life sciences
